X
Xiao-Yu Xu
Publications - 4
Citations - 79
Xiao-Yu Xu is an academic researcher. The author has contributed to research in topics: Regimen & Medicine. The author has an hindex of 2, co-authored 3 publications receiving 13 citations.
Papers
More filters
Journal ArticleDOI
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.
Hongxing Pan,Jian-Kai Liu,Baoying Huang,Gui-Fan Li,Xian-Yun Chang,Ya-Fei Liu,Wenling Wang,Kai Chu,Jialei Hu,Jingxin Li,Dan-Dan Zhu,Jing-Liang Wu,Xiao-Yu Xu,Li Zhang,Meng Wang,Wenjie Tan,Wei-Jin Huang,Fengcai Zhu,Fengcai Zhu +18 more
TL;DR: In this article, the authors report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults, in a phase 1 and phase 2 randomized, double-blind, and placebo-controlled trial.
Posted ContentDOI
Heterologous prime-boost immunization with CoronaVac and Convidecia
Jingxin Li,Li-Hua Hou,Xiling Guo,Pengfei Jin,Shi-Po Wu,Jiahong Zhu,Hongxing Pan,Xue Wang,Zhizhou Song,Jingxuan Wan,Lunbiao Cui,Junqiang Li,Xuewen Wang,Lairun Jin,Jingxian Liu,Fengjuan Shi,Xiao-Yu Xu,Yin Chen,Tao Zhu,Wei Chen,Fengcai Zhu +20 more
TL;DR: In this paper, a randomized, controlled, observer-blinded trial of heterologous prime-boost immunization with CoronaVac and Convidecia in healthy adults 18-59 years of age was conducted.
Posted ContentDOI
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
Hong-Xing Pan,Jian-Kai Liu,Baoying Huang,Gui-Fan Li,Xian-Yun Chang,Ya-Fei Liu,Wen-Ling Wang,Kai Chu,Jialei Hu,Jingxin Li,Dan-Dan Zhu,Jing-Liang Wu,Xiao-Yu Xu,Li Zhang,Meng Wang,Wenjie Tan,Weijin Huang,Fengcai Zhu +17 more
TL;DR: In this article, the authors reported the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults in two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials.
Journal ArticleDOI
Structures and Applications of NIR‐II AIEgens Containing Benzobisthiadiazole Derivatives
TL;DR: AIEgens fluorescent molecular probes in the NIR-II window have attracted much attention owning to their deep penetration, reduction of tissue absorption and scattering, excellent photostability, and low cytotoxicity as discussed by the authors .